Lipid and Nucleic Acid Chemistries: Combining the Best of Both Worlds to Construct Advanced Biomaterials

Baillet, Julie; Desvergnes, Valérie; Hamoud, Aladin; Latxague, Laurent; Barthélémy, Philippe

doi:10.1002/adma.201705078

Cited by 58 publications

(38 citation statements)

References 99 publications

(131 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In previous studies we explored the ability of hybrid nucleolipids 30 to form nanoparticles when formulated to different kinds of therapeutic molecules, including small active pharmaceutical ingredients (API) 31 , siRNA 32 , antisenses 33 . It was demonstrated that the resulting nanocarriers displayed higher biological activities compared to the unformulated drugs.…”

Section: Discussionmentioning

confidence: 99%

Lipid oligonucleotides as a new strategy for tackling the antibiotic resistance

Kauss

Arpin

Bientz

et al. 2020

Sci Rep

Self Cite

View full text Add to dashboard Cite

Antibiotic resistance has become a major issue in public health especially for one of the most used antibiotics; the third-generation cephalosporins. one of the main resistance mechanisms in Enterobacteriaceae, is the production of extended-Spectrum β-lactamases. Here, we demonstrated that the oligonucleotide therapy is an efficient approach to reduce the resistance of bacteria to antibiotic treatment. Lipid oligonucleotides (LONs) were proved to be efficient strategies in both delivering the oligonucleotide sequences in the prokaryotic cells and decreasing the Minimum inhibitory concentration of resistant bacteria to a third generation cephalosporin, the ceftriaxone. Accordingly, we demonstrated the strong antimicrobial potential of this Lon strategy targeting the ß-lactamase activity on both clinical and laboratory strains. our results support the concept that the self-delivery of oligonucleotide sequences via lipid conjugation may be extended to other antimicrobial drugs, which opens novel ways to struggle against the antibiotic resistance.

show abstract

Section: Discussionmentioning

confidence: 99%

Lipid oligonucleotides as a new strategy for tackling the antibiotic resistance

Kauss

Arpin

Bientz

et al. 2020

Sci Rep

Self Cite

View full text Add to dashboard Cite

show abstract

“…Thus, in order to produce more effective Ru(III)-based anticancer agents, able to cross the biological barriers, our research group proposed a prodrug approach. In this design, the active unit, AziRu, has been incorporated into highly functionalized nucleolipid-based scaffolds [101] able to form, under physiological conditions, stable self-assembling aggregates efficiently protecting the metal complex from biological degradation and conveying it through the cell phospholipidic bilayers [77,79,[102][103][104][105][106][107][108][109].…”

Section: Nucleolipid and Aminoacyl Lipid-based Structures Incorporatimentioning

confidence: 99%

Anticancer Ruthenium(III) Complexes and Ru(III)-Containing Nanoformulations: An Update on the Mechanism of Action and Biological Activity

et al. 2019

View full text Add to dashboard Cite

The great advances in the studies on metal complexes for the treatment of different cancer forms, starting from the pioneering works on platinum derivatives, have fostered an increasingly growing interest in their properties and biomedical applications. Among the various metal-containing drugs investigated thus far, ruthenium(III) complexes have emerged for their selective cytotoxic activity in vitro and promising anticancer properties in vivo, also leading to a few candidates in advanced clinical trials. Aiming at addressing the solubility, stability and cellular uptake issues of low molecular weight Ru(III)-based compounds, some research groups have proposed the development of suitable drug delivery systems (e.g., taking advantage of nanoparticles, liposomes, etc.) able to enhance their activity compared to the naked drugs. This review highlights the unique role of Ru(III) complexes in the current panorama of anticancer agents, with particular emphasis on Ru-containing nanoformulations based on the incorporation of the Ru(III) complexes into suitable nanocarriers in order to enhance their bioavailability and pharmacokinetic properties. Preclinical evaluation of these nanoaggregates is discussed with a special focus on the investigation of their mechanism of action at a molecular level, highlighting their pharmacological potential in tumour disease models and value for biomedical applications.

show abstract

“…[19,20] Whereas the main biological role of nucleic acidsi st os tore and process genetic information, lipids are key structurale lementso fm embranes,a sb oundaries that allow the compartmentalizationo fc ellular processes. Merging the properties of nucleic acids or their molecular componentsw ith that of lipids has therefore attracted much attention in recent times, [21] mostlyf or the design of artificial molecular devices [22,23] and varioust herapeutic strategies. [24,25] Herein, we showapossible use of nucleolipids in the context of systems chemistry,t oa chieve control of the self-assembly of lipidic amphiphiles, either pure or in mixtures, leading to different self-assembled nanoand microstructures as af unctiono ft he sequence of nucleobases present in the nucleolipid system.M oreover,s ome of the structures obtained in this work can encapsulate hydrophobic molecules, revealing ap otential as delivery vehicles of hydrophobic drugs or as compartmentst oh ost interesting chemistries in their interior.…”

Section: Introductionmentioning

confidence: 99%

Programmed Recognition between Complementary Dinucleolipids To Control the Self‐Assembly of Lipidic Amphiphiles

Morales-Reina

Giri

Leclercq

et al. 2020

Chemistry A European J

View full text Add to dashboard Cite

One of the major goals in systems chemistry is to create molecular assemblies with emergent properties that are characteristic of life. An interesting approach toward this goal is based on mergingd ifferent biological building blocks into synthetic systems with properties arising from the combination of their molecular components. The covalentl inkage of nucleic acids (or their constituents:n ucleotides,n ucleosides and nucleobases) with lipids in the same hybrid molecule leads, for example, to the so-called nucleolipids. Herein, we describen ucleolipids with av ery short sequence of two nucleobases per lipid, which, in combination with hydrophobic effectsp romoted by the lipophilic chain, allow controlo ft he self-assembly of lipidic amphiphiles to be achieved. The presentw ork describes as pectroscopic and microscopy study of the structural features and dynamic selfassembly of dinucleolipids that contain adenine or thymine moieties, either pure or in mixtures. This approach leads to different self-assembled nanostructures, which include spherical, rectangulara nd fibrillara ssemblies, as af unction of the sequence of nucleobases and chiral effects of the nucleolipidsinvolved.W ealso show evidencethat the resulting architectures can encapsulate hydrophobic molecules,r evealing their potential as drug delivery vehicles or as compartmentstoh ost interesting chemistries in their interior.

show abstract

Lipid and Nucleic Acid Chemistries: Combining the Best of Both Worlds to Construct Advanced Biomaterials

Cited by 58 publications

References 99 publications

Lipid oligonucleotides as a new strategy for tackling the antibiotic resistance

Lipid oligonucleotides as a new strategy for tackling the antibiotic resistance

Anticancer Ruthenium(III) Complexes and Ru(III)-Containing Nanoformulations: An Update on the Mechanism of Action and Biological Activity

Programmed Recognition between Complementary Dinucleolipids To Control the Self‐Assembly of Lipidic Amphiphiles

Contact Info

Product

Resources

About